Company’s 36-month beta value is 1.26.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for CDLX is 49.80M, and currently, short sellers hold a 17.21% ratio of that floaft. The average trading volume of CDLX on June 13, 2025 was 979.29K shares.
CDLX) stock’s latest price update
Cardlytics Inc (NASDAQ: CDLX) has experienced a decline in its stock price by -6.43 compared to its previous closing price of 1.71. However, the company has seen a fall of -4.76% in its stock price over the last five trading days. seekingalpha.com reported 2025-05-26 that We maintain our Strong Buy on Cardlytics and issue a PT of $6, despite the near-term revenue reset and slower monetization from new partners. The Amex channel is a game-changer, offering high-margin, immediate profitability with minimal incremental OpEx, supporting a clear path to EBITDA recovery. EBP and platform diversification are driving structural margin expansion, de-risking revenue and opening new high-engagement verticals for scalable growth.
CDLX’s Market Performance
Cardlytics Inc (CDLX) has seen a -4.76% fall in stock performance for the week, with a -23.81% decline in the past month and a -22.71% plunge in the past quarter. The volatility ratio for the week is 3.35%, and the volatility levels for the past 30 days are at 3.74% for CDLX. The simple moving average for the past 20 days is -12.52% for CDLX’s stock, with a -46.11% simple moving average for the past 200 days.
Analysts’ Opinion of CDLX
Many brokerage firms have already submitted their reports for CDLX stocks, with Evercore ISI repeating the rating for CDLX by listing it as a “In-line.” The predicted price for CDLX in the upcoming period, according to Evercore ISI is $4 based on the research report published on October 11, 2024 of the previous year 2024.
Northland Capital, on the other hand, stated in their research note that they expect to see CDLX reach a price target of $5. The rating they have provided for CDLX stocks is “Market Perform” according to the report published on August 16th, 2024.
BofA Securities gave a rating of “Underperform” to CDLX, setting the target price at $3.50 in the report published on August 15th of the previous year.
CDLX Trading at -7.30% from the 50-Day Moving Average
After a stumble in the market that brought CDLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.64% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDLX starting from DeSieno Alexis, who sale 26,217 shares at the price of $1.94 back on May 15 ’25. After this action, DeSieno Alexis now owns 164,833 shares of Cardlytics Inc, valued at $50,809 using the latest closing price.
DeSieno Alexis, the Officer of Cardlytics Inc, proposed sale 26,217 shares at $1.94 during a trade that took place back on May 15 ’25, which means that DeSieno Alexis is holding shares at $50,809 based on the most recent closing price.
Stock Fundamentals for CDLX
Current profitability levels for the company are sitting at:
- -0.71 for the present operating margin
- 0.43 for the gross margin
The net margin for Cardlytics Inc stands at -0.65. The total capital return value is set at -0.81. Equity return is now at value -135.48, with -38.02 for asset returns.
Based on Cardlytics Inc (CDLX), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at 0.01. The debt to equity ratio resting at 3.44. The interest coverage ratio of the stock is -20.18.
Currently, EBITDA for the company is -152.53 million with net debt to EBITDA at -1.2. When we switch over and look at the enterprise to sales, we see a ratio of 0.93. The receivables turnover for the company is 2.74for trailing twelve months and the total asset turnover is 0.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.19.
Conclusion
In a nutshell, Cardlytics Inc (CDLX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
